GlassScriptPhysician profile
Abhijeet Waghray
NPI 1073878351
$13,086.89
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $1,160 · 2021: $3,890 · 2022: $4,409 · 2023: $2,533 · 2024: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,693.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,788.42 | 2019-2023 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,001.91 | 2019-2023 | Xifaxan, Trulance, Plenvu |
| E.R. Squibb & Sons, L.L.C. | $1,122.62 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $598.36 | 2019-2023 | Stelara |
| Redhill Biopharma INC. | $570.80 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Takeda Pharmaceuticals U.S.A., INC. | $556.01 | 2020-2024 | Entyvio |
| Ferring Pharmaceuticals INC. | $471.22 | 2020-2023 | Rebyota |
| Qol Medical, LLC | $417.23 | 2021-2023 | Sucraid |
| Pfizer INC. | $355.20 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $345.34 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $297.04 | 2021-2023 | Dificid |
| Boston Scientific Corporation | $248.58 | 2022-2024 | Apollo Esg Nxt System |
| Celgene Corporation | $236.12 | 2021-2023 | Zeposia |
| Romark Laboratories, Lc | $143.65 | 2020 | |
| Genzyme Corporation | $137.48 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $128.13 | 2022-2023 | Injectafer |
| Janssen Scientific Affairs, LLC | $120.75 | 2020 | |
| Vivus LLC | $91.64 | 2021-2023 | Qsymia |
| Intercept Pharmaceuticals, INC. | $87.00 | 2020-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $67.36 | 2020-2023 | |
| Blueprint Medicines Corporation | $62.75 | 2022 | |
| Gilead Sciences, INC. | $41.96 | 2021 | |
| Capsovision, INC. | $36.97 | 2023 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $35.25 | 2021 | |
| Braintree Laboratories, INC. | $29.99 | 2021 | |
| Fresenius Kabi USA, LLC | $28.16 | 2023 | |
| Napo Pharmaceuticals INC | $22.53 | 2021 | |
| Endo Pharmaceuticals INC. | $16.97 | 2020 | |
| Shire North American Group INC | $14.79 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhijeet Waghray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.